HIV-1 tat and morphine have interactive effects on oligodendrocyte survival and morphology

GLIA

Volumn 57, Issue 2, 2009, Pages 194-206

  Hauser, Kurt F ^a   Hahn, Yun Kyung ^a   Adjan, Valeriya V ^b   Zou, Shiping ^a   Buch, Shreya K ^b   Nath, Avindra ^c   Bruce Keller, Annadora J ^d   Knapp, Pamela E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

AIDS; Cell death; Drug abuse; Glial cell; Heroin; Myelin; NeuroAIDS; Opioid; Transgenic

Indexed keywords

CASPASE 3; GLIAL FIBRILLARY ACIDIC PROTEIN; MORPHINE; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; NARCOTIC ANALGESIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEGENERATION; CELL DIFFERENTIATION; CELL REGENERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; DRUG TARGETING; DRUG TISSUE LEVEL; EMBRYO; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; STEADY STATE; TRANSGENIC MOUSE; TURNOVER TIME; UPREGULATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; CELL CULTURE; CELL SHAPE; CHEMICALLY INDUCED DISORDER; DEMYELINATING DISEASE; DRUG EFFECT; GENETICS; METABOLISM; MYELIN SHEATH; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SILVER STAINING; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANALGESICS, OPIOID; ANIMALS; APOPTOSIS; CASPASE 3; CELL DIFFERENTIATION; CELL SHAPE; CELL SURVIVAL; CELLS, CULTURED; DEMYELINATING DISEASES; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; MORPHINE; MYELIN SHEATH; OLIGODENDROGLIA; SILVER STAINING; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 60549089453     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20746     Document Type: Article

References (89)

1. Adjan VV, Hauser KF, Bakalkin G, Yakovleva T, Gharibyan A, Scheff SW, Knapp PE. 2007. Caspase-3 activity is reduced after spinal cord injury in mice lacking dynorphin: Differential effects on glia and neurons. Neuroscience 148:724-736.
2. Aksenov MY, Hasselrot U, Wu G, Nath A, Anderson C, Mactutus CF, Booze RM. 2003. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res 987:1-9.
3. Ances BM, Ellis RJ. 2007. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27:86-92.
4. Anthony IC, Arango JC, Stephens B, Simmonds P, Bell JE. 2008. The effects of illicit drugs on the HIV infected brain. Front Biosci 13: 1294-1307.
5. Anthony IC, Bell JE. 2008. The neuropathology of HIV/AIDS. Int Rev Psychiatry 20:15-24.
6. Arnot MI, Bateson AN, Martin IL. 1996. Dimethyl sulfoxide/propylene glycol is a suitable solvent for the delivery of diazepam from osmotic minipumps. J Pharmacol Toxicol Methods 36:29-31.
7. Bell JE, Arango JC, Anthony IC. 2006. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. J Neuroimmune Pharmacol 1:182-191.
8. Bhat RV, Axt KJ, Fosnaugh JS, Smith KJ, Johnson KA, Hill DE, Kinzler KW, Baraban JM. 1996. Expression of the APC tumor suppressor protein in oligodendroglia. Glia 17:169-174.
9. Bonavia R, Bajetto A, Barbero S, Albini A, Noonan DM, Schettini G. 2001. HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat neurons. Biochem Biophys Res Commun 288:301-308.
10. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Ried R, Xu R, Nath A, Knapp PE, Hauser KF. 2008. Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 56:1414-1427.
11. Buch SK, Khurdayan VK, Lutz SE, Knapp PE, El-Hage N, Hauser KF. 2007. Glial-restricted precursors: Patterns of expression of opioid receptors and relationship to HIV-1 Tat and morphine susceptibility in vitro. Neuroscience 146:1546-1554.
12. Burdo TH, Katner SN, Taffe MA, Fox HS. 2006. Neuroimmunity, drugs of abuse, and neuroAIDS. J Neuroimmune Pharmacol 1:41-49.
13. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A. 2001. Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci 21:7598-7607.
14. Campbell DS, Holt CE. 2003. Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. Neuron 37:939-952.
15. Carr DJ, France CP. 1993. Immune alterations in chronic morphine-treated rhesus monkeys. Adv Exp Med Biol 335:35-39.
16. Chao CC, Gekker G, Sheng WS, Hu S, Tsang M, Peterson PK. 1994. Priming effect of morphine on the production of tumor necrosis factor- a by microglia: Implications in respiratory burst activity and human immunodeficiency virus-1 expression. J Pharmacol Exp Ther 269:198-203.
17. Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK. 2002. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59:1563-1567.
18. Christie MJ. 2008. Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction. Br J Pharmacol 154:384-396.
19. Cysique LA, Maruff P, Brew BJ. 2004. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/ acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts. J Neurovirol 10:350-357.
20. Donahoe RM, Falek A. 1988. Neuroimmunomodulation by opiates and other drugs of abuse: Relationship to HIV infection and AIDS. Adv Biochem Psychopharmacol 44:145-158.
21. Drotar D, Olness K, Wiznitzer M, Guay L, Marum L, Svilar G, Hom D, Fagan JF, Ndugwa C, Kiziri-Mayengo R. 1997. Neurodevelopmental outcomes of Ugandan infants with human immunodeficiency virus type 1 infection. Pediatrics 100:E5.
22. 2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50:91-106.
23. El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE, Hauser KF. 2006a. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 178:9-16.
24. El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed J, Bruce-Keller A, Hauser KF. 2006b. HIV Tat1-72 and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 53:132-146.
25. Ensoli F, Wang H, Fiorelli V, Zeichner SL, De Cristofaro MR, Luzi G, Thiele CJ. 1997. HIV-1 infection and the developing nervous system: lineage-specific regulation of viral gene expression and replication in distinct neuronal precursors. J Neurovirol 3:290-298.
26. Feng P, Rahim RT, Cowan A, Liu-Chen LY, Peng X, Gaughan J, Meissler JJ Jr, Adler MW, Eisenstein TK. 2006. Effects of l, j or d opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit. Eur J Pharmacol 534:250-257.
27. Fitting S, Booze RM, Hasselrot U, Mactutus CF. 2008. Differential long-term neurotoxicity of HIV-1 proteins in the rat hippocampal formation: A design-based stereological study. Hippocampus 18:135-147.
28. Garrido C, Kroemer G. 2004. Life's smile, death's grin: Vital functions of apoptosis-executing proteins. Curr Opin Cell Biol 16:639-646.
29. Gensert JM, Goldman JE. 2001. Heterogeneity of cycling glial progenitors in the adult mammalian cortex and white matter. J Neurobiol 48:75-86.
30. Ghafouri M, Amini S, Khalili K, Sawaya BE. 2006. HIV-1 associated dementia: Symptoms and causes. Retrovirology 3:28.
31. Glass JD, Wesselingh SL, Selnes OA, McArthur JC. 1993. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 43:2230-2237.
32. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK. 2002. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 99:13795-13800.
33. Gonzalez-Scarano F, Martin-Garcia J. 2005. The neuropathogenesis of AIDS. Nat Rev Immunol 5:69-81.
34. Gray F, Lescs MC, Keohane C, Paraire F, Marc B, Durigon M, Gherardi R. 1992. Early brain changes in HIV infection: Neuropathological study of 11 HIV seropositive, non-AIDS cases. J Neuropathol Exp Neurol 51:177-185.
35. Gray F, Scaravilli F, Everall I, Chretien F, An S, Boche D, Adle-Biassette H, Wingertsmann L, Durigon M, Hurtrel B, Chiodi F, Bell J, Lantos P. 1996. Neuropathology of early HIV-1 infection. Brain Pathol 6:1-15.
36. Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF. 2001. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 102:555-563.
37. Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, Persidsky Y, Volsky DJ, Knapp PE. 2007. HIV-1 neuropathogenesis: Glial mechanisms revealed through substance abuse. J Neurochem 100: 567-586.
38. Hauser KF, McLaughlin PJ, Zagon IS. 1989. Endogenous opioid systems and the regulation of dendritic growth and spine formation. J Comp Neurol 281:13-22.
39. Hu S, Sheng WS, Lokensgard JR, Peterson PK. 2005. Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 191:886-889.
40. Jana A, Pahan K. 2004. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci 27:9531-9540.
41. Jarskog LF, Gilmore JH, Glantz LA, Gable KL, German TT, Tong RI, Lieberman JA. 2007. Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology 32:95-102.
42. Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C. 2007. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 27:3703-3711.
43. Kandanearatchi A, Williams B, Everall IP. 2003. Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol 13:104-110.
44. Khurdayan VK, Buch S, El-Hage N, Lutz SE, Goebel SM, Singh IN, Knapp PE, Turchan-Cholewo J, Nath A, Hauser KF. 2004. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci 19:3171-3182.
45. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ. 2003. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162:1693-1707.
46. Knapp PE, Hauser KF. 1996. m-Opioid receptor activation enhances DNA synthesis in immature oligodendrocytes. Brain Res 743:341-345.
47. Knapp PE, Itkis OS, Zhang L, Spruce BA, Bakalkin G, Hauser KF. 2001. Opiate signaling in oligodendrocytes: Possible autocrine effects on cell survival and development. Glia 35:156-165.
48. Knapp PE, Maderspach K, Hauser KF. 1998. Endogenous opioid system in developing normal and jimpy oligodendrocytes: m and k opioid receptors mediate differential mitogenic and growth responses. Glia 22:189-201.
49. Kopnisky KL, Bao J, Lin YW. 2007. Neurobiology of HIV, psychiatric and substance abuse comorbidity research: Workshop report. Brain Behav Immun 21:428-441.
50. Kruman II, Nath A, Mattson MP. 1998. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154:276-288.
51. Langford TD, Letendre SL, Larrea GJ, Masliah E. 2003. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 13:195-210.
52. Lanjewar DN, Jain PP, Shetty CR. 1998. Profile of central nervous system pathology in patients with AIDS: An autopsy study from India. AIDS 12:309-313.
53. Launay S, Hermine O, Fontenay M, Kroemer G, Solary E, Garrido C. 2005. Vital functions for lethal caspases. Oncogene 24:5137-5148.
54. Li Y, Merrill JD, Mooney K, Song L, Wang X, Guo CJ, Savani RC, Metzger DS, Douglas SD, Ho WZ. 2003. Morphine enhances HIV infection of neonatal macrophages. Pediatr Res 54:282-288.
55. Ligon KL, Fancy SP, Franklin RJ, Rowitch DH. 2006. Olig gene function in CNS development and disease. Glia 54:1-10.
56. Lipton SA. 1997. Neuropathogenesis of acquired immunodeficiency syndrome dementia. Curr Opin Neurol 10:247-253.
57. Mahajan SD, Aalinkeel R, Reynolds JL, Nair BB, Fernandez SF, Schwartz SA, Nair MP. 2005. Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res 3:277-288.
58. McArthur JC, Becker PS, Parisi JE, Trapp B, Selnes OA, Cornblath DR, Balakrishnan J, Griffin JW, Price D. 1989. Neuropathological changes in early HIV-1 dementia. Ann Neurol 26:681-684.
59. McLaughlin B. 2004. The kinder side of killer proteases: Caspase activation contributes to neuroprotection and CNS remodeling. Apoptosis 9:111-121.
60. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M. 2000. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14:222-227.
61. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, Cass W, Turchan JT. 2002. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 31(Suppl 2):S62-S69.
62. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD. 1996. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 70:1475-1480.
63. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W. 2002. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31:171-177.
64. Noel RJ Jr, Kumar A. 2006. Virus replication and disease progression inversely correlate with SIV tat evolution in morphine-dependent and SIV/ SHIV-infected Indian rhesus macaques. Virology 346:127-138.
65. Oomman S, Finckbone V, Dertien J, Attridge J, Henne W, Medina M, Mansouri B, Singh H, Strahlendorf H, Strahlendorf J. 2004. Active caspase-3 expression during postnatal development of rat cerebellum is not systematically or consistently associated with apoptosis. J Comp Neurol 476:154-173.
66. Oomman S, Strahlendorf H, Finckbone V, Strahlendorf J. 2005. Nonlethal active caspase-3 expression in Bergmann glia of postnatal rat cerebellum. Brain Res Dev Brain Res 160:130-145.
67. Patel CA, Mukhtar M, Pomerantz RJ. 2000. Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74:9717-9726.
68. Peart JN, Gross GJ. 2004. Morphine-tolerant mice exhibit a profound and persistent cardioprotective phenotype. Circulation 109:1219-1222.
69. Peterson PK, Gekker G, Hu S, Cabral G, Lokensgard JR. 2004. Cannabinoids and morphine differentially affect HIV-1 expression in CD4(1) lymphocyte and microglial cell cultures. J Neuroimmunol 147:123-126.
70. Peterson PK, Molitor TW, Chao CC. 1993. Mechanisms of morphine-induced immunomodulation. Biochem Pharmacol 46:343-348.
71. Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, McArthur JC, Trapp BD. 1993. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood-brain barrier. Ann Neurol 34:339-350.
72. Rahim RT, Meissler JJ, Zhang L, Adler MW, Rogers TJ, Eisenstein TK. 2003. Withdrawal from morphine in mice suppresses splenic macrophage function, cytokine production, and costimulatory molecules. J Neuroimmunol 144:16-27.
73. Rozenfeld R, Devi LA. 2007. Receptor heterodimerization leads to a switch in signaling: β-Arrestin2-mediated ERK activation by μ-δ opioid receptor heterodimers. FASEB J 21:2455-2465.
74. Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C. 2008. Opioid addiction and pregnancy: Perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 56:1017-1027.
75. Schwartz L, Major EO. 2006. Neural progenitors and HIV-1-associated central nervous system disease in adults and children. Curr HIV Res 4:319-327.
76. Schweitzer C, Keller F, Schmitt MP, Jaeck D, Adloff M, Schmitt C, Royer C, Kirn A, Aubertin AM. 1991. Morphine stimulates HIV replication in primary cultures of human Kupffer cells. Res Virol 142:189-195.
77. Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, Knapp PE, Nath A, Hauser KF. 2004. Apoptotic death of striatal neurons induced by HIV-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. J Neurovirol 10:141-151.
78. Sommer I, Schachner M. 1982. Cells that are O4 antigen-positive and O1 antigen-negative differentiate into O1 antigen-positive oligodendrocytes. Neurosci Lett 29:183-188.
79. Stiene-Martin A, Knapp PE, Martin K, Gurwell JA, Ryan S, Thornton SR, Smith FL, Hauser KF. 2001. Opioid system diversity in developing neurons, astroglia, and oligodendroglia in the subventricular zone and striatum: Impact on gliogenesis in vivo. Glia 36: 78-88.
80. Suzuki S, Carlos MP, Chuang LF, Torres JV, Doi RH, Chuang RY. 2002. Methadone induces CCR5 and promotes AIDS virus infection. FEBS Lett 519:173-177.
81. Trillo-Pazos G, McFarlane-Abdulla E, Campbell IC, Pilkington GJ, Everall IP. 2000. Recombinant nef HIV-IIIB protein is toxic to human neurons in culture. Brain Res 864:315-326.
82. Tryoen-Toth P, Gaveriaux-Ruff C, Labourdette G. 2000. Down-regulation of l-opioid receptor expression in rat oligodendrocytes during their development in vitro. J Neurosci Res 60:10-20.
83. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, Peng X, Chen KC, Chauhan A, Haughey N, Cutler R, Mattson MP, Pardo C, Conant K, Sacktor N, McArthur JC, Hauser KF, Gairola C, Nath A. 2006. Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: Protection by diosgenin and L-deprenyl. Neurobiol Dis 23:109-119.
84. Vallejo R, de Leon-Casasola O, Benyamin R. 2004. Opioid therapy and immunosuppression: A review. Am J Ther 11:354-365.
85. Van Rie A, Harrington PR, Dow A, Robertson K. 2007. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol 11:1-9.
86. Wolswijk G, Noble M. 1989. Identification of an adult-specific glial progenitor cell. Development 105:387-400.
87. Woodruff RH, Tekki-Kessaris N, Stiles CD, Rowitch DH, Richardson WD. 2001. Oligodendrocyte development in the spinal cord and telencephalon: Common themes and new perspectives. Int J Dev Neurosci 19:379-385.
88. Yang JY, Michod D, Walicki J, Murphy BM, Kasibhatla S, Martin SJ, Widmann C. 2004a. Partial cleavage of RasGAP by caspases is required for cell survival in mild stress conditions. Mol Cell Biol 24:10425-10436.
89. Yang JY, Michod D, Walicki J, Widmann C. 2004b. Surviving the kiss of death. Biochem Pharmacol 68:1027-1031.